
Opinion|Videos|April 11, 2025
Key Limitations of MAIC Analyses
Author(s)Arun Azad, PhD, MBBS
A panelist discusses how Matching-Adjusted Indirect Comparison (MAIC) analyses are limited by potential unmeasured confounding factors, small effective sample sizes after matching, and reliance on published aggregate data, which should be carefully considered when interpreting findings as complementary rather than definitive evidence for treatment decisions.
Advertisement
Episodes in this series

Summary for Physicians: Limitations of MAIC Analyses
MAIC analyses, although useful, have several important methodological limitations:
- Potential unmeasured confounding factors may still bias results despite matching procedures.
- Effective sample sizes are often substantially reduced after matching, limiting statistical power.
- Reliance on aggregate published data rather than individual patient data introduces additional uncertainty.
When reviewing MAIC analyses, consider these findings as complementary evidence rather than definitive proof for treatment decisions. These analyses should be interpreted within the broader context of available clinical evidence.
Advertisement
Related to this article

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
The UroOnc Minute: The Role of Language in Cancer Care, With Jessica Rett, PhD
5


